Flora Zagouri

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer

Shanu Modi, William Jacot, Toshinari Yamashita et al. · New England Journal of Medicine · 2022 · 2.5K citations · Full text

Medicine, Oncology, Pharmacology +17

Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial

Domenica Lorusso, Yang Xiang, Kosei Hasegawa et al. · The Lancet · 2024 · 349 citations

Medicine, Oncology, Pharmacotherapy +13

Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial

Fabrice André, Yeon Hee Park, Sung‐Bae Kim et al. · The Lancet · 2023 · 345 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial

Domenica Lorusso, Yang Xiang, Kosei Hasegawa et al. · The Lancet · 2024 · 161 citations

Medicine, Oncology, Pharmacotherapy +12

Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement

Hatem A. Azim, Stefan Michiels, Flora Zagouri et al. · Annals of Oncology · 2013 · 132 citations · Full text

Medicine, Genetics, Oncology +17